Shanghai Raas Blood Products Co., Ltd. Class ASZSE: 002252

Shanghai RAAS Blood Products: 2024 saw robust profit growth, Haier control, and strategic expansion for Shanghai RAAS

· Issued by Shanghai Raas Blood Products Co., Ltd. Class A

Shanghai RAAS achieved 2.67% revenue growth and 23.25% net profit growth in 2024, completed a major change in control to Haier Group, and announced a significant acquisition to expand plasma resources, while maintaining strong margins and investing in R&D.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Shanghai Raas Blood Products Co., Ltd. Class A

All Shanghai Raas Blood Products Co., Ltd. Class A news releases